Primary Membranous Nephropathy

The FDA has granted orphan drug designation for felzartamab, an antibody-mediated rejection therapy for kidney transplant recipients, according to a press release.

The FDA has granted breakthrough therapy designation for felzartamab, an investigational antibody to treat primary membranous nephropathy.